Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: A review of the literature

Seminars in Neurology

Volumn 24, Issue 4, 2004, Pages 395-404

  Colocci, Natalia ^a   Glantz, Michael ^b   Recht, Lawrence ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

CNS prophylaxis; Intraventricular chemotherapy; Leptomeningeal lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; METHOTREXATE; STEROID; THIOTEPA;

CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; IRRADIATION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; REVIEW LITERATURE; RISK FACTORS;

EID: 11344273421     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861534     Document Type: Review

References (43)

1. Recht L, Mrugala M. Neurologic complications of hematologic neoplasms. Neurol Clin 2003;21:87-105
2. Mrugala M, Recht L. Neurological complications of Hodgkin's disease. In: Batchelor T, ed. Lymphoma of the Nervous System. Boston: Butterworth-Heinemann; 2004:123-132
3. Rappaport H. Tumors of the hematopoietic system. Atlas of Tumor Pathology, Series I, Section III, Fascicle 8. Washington, DC: Armed Forces Institute of Pathology; 1966
4. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002;95:576-580
5. Lennert K, Feller AC. Histopathology of Non-Hodgkin's Lymphoma (according to the up-dated Kiel classification). Berlin: Springer; 1992
6. Project NH. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135
7. Harris NL, Jaffee ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392
8. Jaffee ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001
9. Hiddemann W, Longo DL, Coiffier B, et al. Lymphoma classification - The gap between biology and clinical management is closing. Blood 1996;88:4085-4089
10. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte E. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13: 1099-1107
11. Bos GMJ, van Putten WL, van der Holt B, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Ann Oncol 1998;9:191-194
12. Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999;32:571-576
13. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000;11:685-690
14. Tomita N, Kodama F, Sakai R, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of a very high serum LDH concentration. Leuk Lymphoma 2000;38:335-343
15. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin's lymphoma. Arch Neurol 1997;54:854-859
16. van Biesen K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178-1184
17. Ersbøll J, Schultz HB, Thomsen BLR, Keiding N, Nissen NI. Meningeal involvement by non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985;35:487-496
18. Hoerni-Simon G, Suchaud JP, Eghbali H, Coindre JM, Hoerni B. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. Oncology 1987;44:98-101
19. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990;8:141-145
20. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991;14:478-482
21. Keldsen N, Michalski W, Bentzen S, Hansen K, Thorling K. Risk factors for central nervous system involvement in non-Hodgkin's lymphoma. Acta Oncol 1996;35:703-708
22. Wolf MM, Cooper IA, Olver IN, et al. Non-Hodgkin's lymphoma involving the central nervous system. Aust N Z J Med 1985;15:16-20
23. Recht L, Straus DJ, Cirrincione C, et al. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988;84:425-433
24. Bunn PA, Schein PS, Banks PM, et al. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976; 47:3-10
25. Mackintosh FR, Colby TV, Podolsky WJ, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982;49:586-595
26. Cairncross JG, Posner JB. Neurological complications of malignant lymphoma. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing; 1980:27-62
27. Lokich J, Galbo C. Leptomeningeal lymphoma: perspectives on management. Cancer Treat Rev 1981;8:103-110
28. Griffin JW, Thompson RW, Mitchinson MJ, et al. Lymphomatous leptomeningitis. Am J Med 1971;51:200-208
29. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-229
30. Glantz MJ, Cole BF, Glantz L, et al. Cerebrospinal fluid cytology in patients with cancer: how to minimize false negative results. Cancer 1998;82:733-739
31. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57
32. Collie DA, Brush JP, Lammie GA, et al. Imaging features of leptomeningeal metastases. Clin Radiol 1999;54:765-771
33. Glantz MJ, Cole BF, Recht L, et al. High dose intravenous methotrexate for patients with leptomeningeal carcinomatosis: is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16:1561-1567
34. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995;75:2919-2931
35. Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002;43:587-593
36. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993;11:561-569
37. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110-3116
38. Sullivan MP, Chen T, Dyment PG, et al. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood 1982;60:948-958
39. Chua SL, Seymor JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002;43:1783-1788
40. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983;1:91-98
41. Perez-Soler R, Smith TL, Cabinillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 1986;57:971-977
42. Johnson GJ, Oken MM, Anderson JR, et al. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet 1984;2:685-687
43. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-145